EVI1 promotes tumor growth via transcriptional repression of MS4A3

被引:28
作者
Heller, Gerwin [1 ,2 ]
Rommer, Anna [1 ,2 ]
Steinleitner, Katarina [1 ,2 ]
Etzler, Julia [1 ,2 ]
Hackl, Hubert [3 ]
Heffeter, Petra [2 ,4 ,5 ]
Tomasich, Erwin [1 ,2 ]
Filipits, Martin [2 ,4 ,5 ]
Steinmetz, Birgit [1 ,2 ]
Topakian, Thais [1 ,2 ]
Klingenbrunner, Simone [1 ,2 ]
Ziegler, Barbara [1 ,2 ]
Spittler, Andreas [6 ]
Zoechbauer-Mueller, Sabine [1 ,2 ]
Berger, Walter [2 ,4 ,5 ]
Wieser, Rotraud [1 ,2 ]
机构
[1] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria
[2] Med Univ Vienna, Ctr Comprehens Canc, A-1090 Vienna, Austria
[3] Med Univ Innsbruck, Div Bioinformat, Bioctr, A-6020 Innsbruck, Austria
[4] Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria
[5] Res Platform Translat Canc Therapy Res, A-1090 Vienna, Austria
[6] Med Univ Vienna, Core Facil Flow Cytometry & Surg Res Labs, A-1090 Vienna, Austria
基金
奥地利科学基金会;
关键词
EVI1; MS4A3; Transcriptional repression; Myeloid leukemia; Tumor growth; ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION SIGNATURE; CELL-CYCLE PROGRESSION; ZINC FINGERS; CONSENSUS SEQUENCE; TRANSFORMING GENE; FORCED EXPRESSION; DOWN-REGULATION; SELF-RENEWAL; KINASE;
D O I
10.1186/s13045-015-0124-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The transcription factor Ecotropic Virus Integration site 1 (EVI1) regulates cellular proliferation, differentiation, and apoptosis, and its overexpression contributes to an aggressive course of disease in myeloid leukemias and other malignancies. Notwithstanding, knowledge about the target genes mediating its biological and pathological functions remains limited. We therefore aimed to identify and characterize novel EVI1 target genes in human myeloid cells. Methods: U937T_EVI1, a human myeloid cell line expressing EVI1 in a tetracycline regulable manner, was subjected to gene expression profiling. qRT-PCR was used to confirm the regulation of membrane-spanning-4-domains subfamily-A member-3 (MS4A3) by EVI1. Reporter constructs containing various parts of the MS4A3 upstream region were employed in luciferase assays, and binding of EVI1 to the MS4A3 promoter was investigated by chromatin immunoprecipitation. U937 derivative cell lines experimentally expressing EVI1 and/or MS4A3 were generated by retroviral transduction, and tested for their tumorigenicity by subcutaneous injection into severe combined immunodeficient mice. Results: Gene expression microarray analysis identified 27 unique genes that were up-regulated, and 29 unique genes that were down-regulated, in response to EVI1 induction in the human myeloid cell line U937T. The most strongly repressed gene was MS4A3, and its down-regulation by EVI1 was confirmed by qRT-PCR in additional, independent experimental model systems. MS4A3 mRNA levels were also negatively correlated with those of EVI1 in several published AML data sets. Reporter gene assays and chromatin immunoprecipitation showed that EVI1 regulated MS4A3 via direct binding to a promoter proximal region. Experimental re-expression of MS4A3 in an EVI1 overexpressing cell line counteracted the tumor promoting effect of EVI1 in a murine xenograft model by increasing the rate of apoptosis. Conclusions: Our data reveal MS4A3 as a novel direct target of EVI1 in human myeloid cells, and show that its repression plays a role in EVI1 mediated tumor aggressiveness.
引用
收藏
页数:14
相关论文
共 78 条
[1]   Comparative gene expression analysis of a chronic myelogenous leukemia c-ell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors [J].
Bao, Fei ;
Polk, Paula ;
Nordberg, Mary L. ;
Veillon, Diana M. ;
Sun, Amanda ;
Deininger, Michael ;
Murray, David ;
Andersson, Borje S. ;
Munker, Reinhold .
LEUKEMIA RESEARCH, 2007, 31 (11) :1511-1520
[2]   Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors [J].
Bard-Chapeau, Emilie A. ;
Jeyakani, Justin ;
Kok, Chung H. ;
Muller, Julius ;
Chua, Belinda Q. ;
Gunaratne, Jayantha ;
Batagov, Arsen ;
Jenjaroenpun, Piroon ;
Kuznetsov, Vladimir A. ;
Wei, Chia-Lin ;
D'Andrea, Richard J. ;
Bourque, Guillaume ;
Jenkins, Nancy A. ;
Copeland, Neal G. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (06) :2168-2173
[3]   Ontologizer 2.0 - a multifunctional tool for GO term enrichment analysis and data exploration [J].
Bauer, Sebastian ;
Grossmann, Steffen ;
Vingron, Martin ;
Robinson, Peter N. .
BIOINFORMATICS, 2008, 24 (14) :1650-1651
[4]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[5]   EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs [J].
Bindels, Eric M. J. ;
Havermans, Marije ;
Lugthart, Sanne ;
Erpelinck, Claudia ;
Wocjtowicz, Elizabeth ;
Krivtsov, Andrei V. ;
Rombouts, Elwin ;
Armstrong, Scott A. ;
Taskesen, Erdogan ;
Haanstra, Jurgen R. ;
Beverloo, H. Berna ;
Doehner, Hartmut ;
Hudson, Wendy A. ;
Kersey, John H. ;
Delwel, Ruud ;
Kumar, Ashish R. .
BLOOD, 2012, 119 (24) :5838-5849
[6]   JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update [J].
Bryne, Jan Christian ;
Valen, Eivind ;
Tang, Man-Hung Eric ;
Marstrand, Troels ;
Winther, Ole ;
da Piedade, Isabelle ;
Krogh, Anders ;
Lenhard, Boris ;
Sandelin, Albin .
NUCLEIC ACIDS RESEARCH, 2008, 36 :D102-D106
[7]   EVI1 induces myelodysplastic syndrome in mice [J].
Buonamici, S ;
Li, DL ;
Chi, YQ ;
Zhao, R ;
Wang, XR ;
Brace, L ;
Ni, HY ;
Saunthararajah, Y ;
Nucifora, G .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (05) :713-719
[8]   Binding of HTm4 to cyclin-dependent kinase (cdk)-associated phosphatase (KAP)•cdk2•cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of cdk2 [J].
Chinami, M ;
Yano, Y ;
Yang, X ;
Salahuddin, S ;
Moriyama, K ;
Shiroishi, M ;
Turner, H ;
Shirakawa, T ;
Adra, CN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) :17235-17242
[9]   EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors [J].
Daghistani, Mustafa ;
Marin, David ;
Khorashad, Jamshid Sorouri ;
Wang, Lihui ;
May, Philippa C. ;
Paliompeis, Christos ;
Milojkovic, Dragana ;
De Melo, Valeria A. ;
Gerrard, Gareth ;
Goldman, John M. ;
Apperley, Jane F. ;
Clark, Richard E. ;
Foroni, Letizia ;
Reid, Alistair G. .
BLOOD, 2010, 116 (26) :6014-6017
[10]   EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells [J].
De Weer, An ;
Van der Meulen, Joni ;
Rondou, Pieter ;
Taghon, Tom ;
Konrad, Torsten A. ;
De Preter, Katleen ;
Mestdagh, Pieter ;
Van Maerken, Tom ;
Van Roy, Nadine ;
Jeison, Marta ;
Yaniv, Isaac ;
Cauwelier, Barbara ;
Noens, Lucien ;
Poirel, Helene-Antoine ;
Vandenberghe, Peter ;
Lambert, Frederic ;
De Paepe, Anne ;
Sanchez, Maria Garcia ;
Odero, Maria ;
Verhasselt, Bruno ;
Philippe, Jan ;
Vandesompele, Joke ;
Wieser, Rotraud ;
Dastugue, Nicole ;
Van Vlierberghe, Pieter ;
Poppe, Bruce ;
Speleman, Frank .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (03) :337-348